PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

- Duchatel, Ryan J., Jackson, Evangeline R., Kearney, Padraic S., Jamaluddin, M. Fairuz B., Douglas, Alicia M., Beitaki, Tyrone, McEwen, Holly P., Persson, Mika L., Hocke, Emily A., Jain, Vaibhav, Aksu, Michael, Manning, Elizabeth E., Parackal, Sarah G., Murray, Heather C., Verrills, Nicole M., Hua, Susan, Cairns, Murray J., Alvaro, Frank, Dayas, Christopher V., Dun, Matthew D., Hua, S, de Bock, CE, Colino-Sanguino, Y, Kiltschewskij, Dylan, Valdes-Mora, F, Tsoli, M, Ziegler, DS, Cairns, MJ, Raabe, EH, Vitanza, NA, Hulleman, E, Phoenix, TN, Koschmann, C, Alvaro, F, Findlay, Izac J., Dayas, CV, Tinkle, CL, Wheeler, H, Whittle, JR, Eisenstat, DD, Firestein, R, Mueller, S, Valvi, S, Hansford, JR, Ashley, DM, Mannan, Abdul, Gregory, SG, Kilburn, LB, Nazarian, J, Cain, JE, Dun, MD, Staudt, Dilana E., Thomas, Bryce C., Germon, Zacary P., Laternser, Sandra

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma

- Jackson, Evangeline R., Duchatel, Ryan J., Le Grand, Marion, Kearney, Padraic S., Douglas, Alicia M., Findlay, Izac J., Germon, Zacary P., McEwen, Holly P., Beitaki, Tyrone S., Patabendige, Adjanie, Skerrett-Byrne, David A., Nixon, Brett, Staudt, Dilana E., Smith, Nathan D., Day, B, Manoharan, N, Nagabushan, S, Hansford, JR, Govender, D, McCowage, GB, Firestein, R, Howlett, M, Endersby, R, Persson, Mika L., Gottardo, NG, Alvaro, F, Waszak, SM, Larsen, MR, Colino-Sanguino, Y, Valdés-Mora, F, Rakotomalala, A, Meignan, S, Pasquier, E, Andre, N, Mannan, Abdul, Hulleman, E, Eisenstat, DD, Vitanza, NA, Nazarian, J, Koschmann, C, Mueller, S, Cain, JE, Dun, MD, Yadavilli, Sridevi, Parackal, Sarah, Game, Shaye, Chong, Wai Chin, Jayasekara, W. Samantha N.

PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

- Alhalabi, Karam T., Stichel, Damian, Pajtler, Kristian W., Snuderl, Matija, Jour, George, Delorenzo, Michael, Martin, Allison M., Levy, Adam, Dalvi, Nagma, Hansford, Jordan R., Gottardo, Nicholas G., Uro-Coste, Emmanuelle, Sievers, Philipp, Alvaro, Frank, Godfraind, C, Vandenbos, F, Pietsch, T, Kramm, C, Filippidou, M, Kattamis, A, Jones, C, Ora, I, Mikkelsen, TS, Peterziel, Heike, Zapotocky, M, Sumerauer, D, Scheie, D, McCabe, M, Wesseling, P, Tops, BBJ, Kranendonk, MEG, Karajannis, MA, Bouvier, N, Papaemmanuil, E, Sommerkamp, Alexander C., Dohmen, H, Acker, T, von Hoff, K, Schmid, S, Miele, E, Filipski, K, Kitanovski, L, Krskova, L, Gojo, J, Haberler, C, Sturm, Dominik, Alvaro, F, Ecker, J, Selt, F, Milde, T, Witt, O, Oehme, I, Kool, M, von Deimling, A, Korshunov, A, Pfister, SM, Wittmann, Andrea, Sahm, F, Jones, DTW, Sill, Martin, Jäger, Natalie, Beck, Pengbo

Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia

- Dun, Matthew D., Mannan, Abdul, Germon, Zacary, Faulkner, Sam, Chi, Mengna, Skerrett-Byrne, David, Murray, Heather C., Flanagan, Hayley, Almazi, Juhura G., Hondermarck, Hubert, Nixon, Brett, De Iuliis, Geoff, Rigby, Callum J., Chamberlain, J, Alvaro, F, de Bock, CE, Morris, JC, Enjeti, Anoop K., Verrills, Nicole M., Butler, Stephen, Toop, Hamish D., Beck, Dominik, Connerty, Patrick, Sillar, Jonathan, Kahl, Richard G. S., Duchatel, Ryan J.